Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Jubilant Pharmova Plunges 4%; BSE HEALTHCARE Index Down 1.0%
Thu, 3 Oct 9:20

Jubilant Pharmova Plunges 4%; BSE HEALTHCARE Index Down 1.0%Image source: Sefa Ozel/www.istockphoto.com

Jubilant Pharmova share price has plunged 4% and is presently trading at Rs 1,120.1.

Meanwhile, the BSE HEALTHCARE index is at 43,814.5 (down 1.0%).

Among the top losers in the BSE HEALTHCARE index today are KIMS (down 9.6%) and CAPLIN POINT (down 3.3%).

DR. LAL PATHLABS (up 0.7%) and Cadila Healthcare are among the top gainers today.

Over the last one year, Jubilant Pharmova has moved up from Rs 435.6 to Rs 1,120.1, registering a gain of Rs 684.5 (up 157.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,428.9 to 43,814.5, registering a gain of 54.1% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 157.1%), SUVEN PHARMACEUTICALS (up 105.3%) and Glenmark Pharma (up 96.0%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 83,002.1 (down 1.5%).

The top losers among the BSE Sensex today are Asian Paints (down 3.0%) and Tata Motors (down 2.9%). The most traded stocks in the BSE Sensex are HDFC Bank and Tata Steel.

In the meantime, NSE Nifty is at 25,452.9 (down 1.3%). BPCL and Bajaj Auto are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,512.1 to 83,002.1, registering a gain of 17,490.0 points (up 26.7%).

Jubilant Pharmova Financial Update...

Jubilant Pharmova net profit grew 6410.8% YoY to Rs 4,818 million for the quarter ended June 2024, compared to a profit of Rs 74 million a year ago. Net sales rose 9.1% to Rs 17,317 million during the period as against Rs 15,869 million in April-June 2023.

For the year ended March 2024, Jubilant Pharmova reported 212.0% increase in net profit to Rs 727 million compared to net loss of Rs 649 million during FY23. Revenue of the company grew 6.7% to Rs 67,029 million during FY24.

The current Price to earnings ratio of Jubilant Pharmova, based on rolling 12 month earnings, stands at 34.1.


Equitymaster requests your view! Post a comment on "Jubilant Pharmova Plunges 4%; BSE HEALTHCARE Index Down 1.0%". Click here!